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Abstract
Objective
To describe disparities along the depression treatment cascade, from indication for antide-
pressant treatment to effective treatment, in HIV-infected individuals by gender and race/
ethnicity.
Methods
The Center for AIDS Research (CFAR) Network of Integrated Clinical Systems (CNICS)
cohort includes 31,000 HIV-infected adults in routine clinical care at 8 sites. Individuals
were included in the analysis if they had a depressive symptoms measure within one month
of establishing HIV care at a CNICS site. Depressive symptoms were measured using the
validated Patient Health Questionnaire-9 (PHQ-9). Indication for antidepressant treatment
was defined as PHQ-9 10 or a current antidepressant prescription. Antidepressant treat-
ment was defined as a current antidepressant prescription. Evidence-based antidepressant
treatment was considered treatment changes based on a person’s most recent PHQ-9, in
accordance with clinical guidelines. We calculated the cumulative probability of moving
through the depression treatment cascade within 24 months of entering CNICS HIV care.
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We used multivariable Cox proportional hazards models to estimate associations between
gender, race/ethnicity, and a range of depression outcomes.
Results
In our cohort of HIV-infected adults in routine care, 47% had an indication for antidepressant
treatment. Significant drop-offs along the depression treatment cascade were seen for the
entire study sample. However, important disparities existed. Women were more likely to
have an indication for antidepressant treatment (HR 1.54; 95% CI 1.34, 1.78), receive anti-
depressant treatment (HR 2.03; 95% CI 1.53, 2.69) and receive evidence-based antide-
pressant treatment (HR 1.67; 95% CI 1.03, 2.74), even after accounting for race/ethnicity.
Black non-Hispanics (HR 0.47, 95% CI 0.35, 0.65), Hispanics (HR 0.63, 95% CI 0.44, 0.89)
and other race/ethnicities (HR 0.35, 95% CI 0.17, 0.73) were less likely to initiate antide-
pressant treatment, compared to white non-Hispanics.
Conclusions
In our cohort of HIV-infected adults depressive symptoms were common. Important dispari-
ties in the prevalence of depressive symptoms and receipt of antidepressant treatment
existed by gender and race/ethnicity.
Introduction
Depression affects an estimated 30% of HIV-infected adults, making it the most commonly
reported mental health condition among adults in HIV care.[1, 2]. For people living with HIV
(PLHIV), depression negatively affects quality of life,[3–5] and is consistently associated with
reduced antiretroviral (ART) adherence, [6–11] viral suppression,[12–14] and higher mortality
rates.[12, 14] Despite the high prevalence of depression and its association with poor outcomes
among HIV-infected adults, depression remains widely unrecognized, untreated, or under-
treated in HIV clinical care.[15, 16]
The “depression treatment cascade”, similar to the HIV treatment cascade, estimates the
proportion of HIV-infected adults with depression whose condition is recognized clinically,
treated, and remits. Estimates of the depression treatment cascade suggest that less than half of
all cases of depression are recognized clinically. Of cases recognized clinically, only half receive
any mental health treatment, and fewer than half of those treated receive guideline-concordant
treatment.[17] Although these large gaps in depression identification and treatment among
HIV-infected patients are well documented, little is known about gender and racial/ethnic dis-
parities that may exist in this cascade.
In the general population, disparities in the prevalence, diagnosis, and treatment of depres-
sion are complex. A higher lifetime prevalence of depression has been reported among white
non-Hispanics (18%), compared to black non-Hispanics (11%) and Hispanics (14%).[18]
However, black Americans are also more likely to be undiagnosed[19] and to experience more
severe or persistent depression.[20, 21] Hispanics and black Americans are also less likely to
receive antidepressant medication,[22–24] including treatment that conforms to current clini-
cal guidelines [21, 25] or to be referred for counseling.[26, 27] Disparities in depression care by
gender also exist. Compared to men, women are significantly more likely be diagnosed with
depression [28] and to utilize mental health services.[29, 30] Differences in the assessment of
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depression between studies, from a diagnosis of major depressive disorder using the Diagnostic
and Statistical Manual of Mental Disorders [31] to validated scales which screen for depressive
symptoms, such as the Patient Health Questionaire-9, [32] further complicates our under-
standing of disparities in depression prevalence and treatment.
Less is known about disparities in depression care that may exist in HIV-infected popula-
tions by gender or race/ethnicity. As HIV transitions from an acute to a chronic medical condi-
tion, high-quality mental health services to ensure the long-term health of HIV-infected adults
are increasingly important. In the United States, HIV disproportionately affects men who have
sex with men (MSM) and women in the southern United States–two groups also at high risk of
depression.[28, 33–36] Given the high burden of depression among HIV-infected adults and
disparities by gender and race/ethnicity in the general population, understanding disparities in
depression care among HIV-infected adults is essential to optimize mental health and clinical
outcomes.
The goal of the present analysis is to describe disparities along the depression treatment cas-
cade by gender and race/ethnicity in a large cohort of HIV-infected adults in the United States.
We report on differences by gender and race/ethnicity in the cumulative probability of success-
fully moving through the depression treatment cascade, from indication for antidepressant
treatment to effective treatment, and estimate the association between gender, race/ethnicity
and a range of depression-related outcomes.
Materials and Methods
Data for the present analysis come from the Center for AIDS Research (CFAR) Network of
Integrated Clinical Systems (CNICS) cohort. The CNICS cohort includes over 31,000 HIV-
infected adults in routine HIV clinical care at 8 sites in the United States.[37] CNICS collects
detailed information on demographic characteristics, ART, antidepressant medications, HIV/
AIDS clinical events, co‐morbid conditions, HIV‐related laboratory values and vital status on
patients who consent to participate. Starting between 2005 and 2011, patients in CNICS also
began completing self-administered socio‐behavioral questionnaires, or Patient‐Reported Out-
comes (PROs), on touch-screen tablets as part of routine care visits. HIV-infected patients
complete PROs approximately every 4–6 months, although this varies based on clinical care
follow-up. Written informed consent was obtained from all study participants and docu-
mented at each CNICS site. Ethical approval for the use of routinely collected clinical data was
provided by the institutional review board at the University of North Carolina at Chapel Hill.
Study Population
The present analysis includes HIV-infected individuals in CNICS who had a PRO measure,
which includes a depression measure, within one month of establishing HIV care at a CNICS
site. For this study, we selected two CNICS sites that routinely initiate the PRO assessment at
the initial visit (Site A and Site B). Site A is in the southern United States and Site B is in the
western United States. Several CNICS sites typically wait until the 2nd or later follow-up visit
for the initial PRO assessment due to competing clinical demands for a patient who is new to
HIV care, such as introducing the patient to the case manager, addressing insurance and fiscal
concerns, etc. Furthermore, the two sites selected provide substantial clinical and racially/eth-
nic diversity including Hispanics, African-Americans, and women. Participants were followed
from entry into care at a CNICS site for up to 24 months or until a depression-related outcome
(defined below), administrative censoring in September or October, 2014 (depending on site),
loss to follow-up (LTFU; defined as 12 months after a participant’s last HIV visit) or death,
whichever date came first.
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Measures
Each PRO includes an assessment of depressive symptoms using the Patient Health Question-
naire-9 (PHQ-9).[32] The PHQ-9 has been widely validated, including among HIV-infected
populations.[38, 39] PROs also include several other validated measures for mental health and
substance use, including: panic disorder (Patient Health Questionnaire-5),[40] high risk alco-
hol use (The Alcohol Use Disorders Identification Test (AUDIT), defined as 4 for males
and 3 for females),[41] and use of illicit drugs including cocaine/crack, heroin/opiates, crys-
tal/amphetamine use, but excluding marijuana (The Alcohol, Smoking and Substance Involve-
ment Screening Test (ASSIST)).[42, 43] Information on counseling-based depression
treatment is not available in CNICS.
For the present analysis, we focused on disparities in indication, receipt and quality of anti-
depressant treatment among HIV-infected adults (Fig 1; Table 1). We defined indication for
antidepressant treatment as a PHQ-9 total score 10 (88% sensitivity and specificity to indi-
cate a major depressive episode)[32] or prescription of an antidepressant. Receipt of antide-
pressant treatment was defined as prescription of an antidepressant medication. Quality of
antidepressant treatment was considered to be evidence-based or not evidence-based. Evi-
dence-based antidepressant treatment was defined as adjusting the antidepressant prescription
based on follow-up depressive severity measures in a manner consistent with evidence-based
guidelines. [44, 45] Specifically, for patients on antidepressant treatment, if a follow-up PHQ-9
score was10 (indicating persistent depressive symptoms) and either the antidepressant dose
was increased or a switch or augmentation of the antidepressant regimen was prescribed, this
was considered active evidence-based treatment. Whereas if no medication adjustment
occurred, this was considered not to be evidence-based treatment. If the follow-up PHQ-9
score was<10, then both changes to and maintenance of the antidepressant regimen were con-
sidered to be (passive) evidence-based. Secondary outcomes considered were mild depressive
symptoms (PHQ-9 between 5 and 9), and depression remission (PHQ-9<5).[46] We exam-
ined depression-related outcomes stratified by gender (female or male) and race/ethnicity
(white, non-Hispanic; black, non-Hispanic, Hispanic, or other).
Fig 1. The depression treatment cascade for HIV-infected adults.
doi:10.1371/journal.pone.0160738.g001
Table 1. Depression-related outcomes and definitions.
Outcome Definition
Indication for antidepressant
treatment
PHQ-9 10 or current antidepressant medication prescription
Antidepressant treatment Current antidepressant medication prescription
Evidence-based antidepressant
treatment
Among those on an antidepressant: Dose increase or medication
switch following a PHQ-9 score 10; dose increase, medication
switch, or no change following a PHQ-9 score <10.
Active evidence-based
antidepressant treatment
Among those on an antidepressant: Dose increase or medication
switch following a PHQ-9 score 10.
Mild depressive symptoms PHQ-9 5–9
Depression remission PHQ-9 <5 among patients taking an antidepressant
doi:10.1371/journal.pone.0160738.t001
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Data Analysis
To understand disparities in depression treatment and response across the depression treat-
ment cascade, we conducted three analyses–each examining a different aspect of the depression
treatment experience. First, to understand the likelihood of a person sequentially moving
through the depression treatment cascade, we looked at each individual’s antidepressant treat-
ment experience over 24 months and calculated the cumulative probability of ever having an
indication for antidepressant treatment, ever initiating antidepressant treatment, ever receiving
evidence-based antidepressant treatment, and ever receiving active evidence-based antidepres-
sant treatment. The cumulative probability of each event was defined as the probability of
experiencing an event, multiplied by the probability of experiencing each previous event on the
depression treatment cascade.
Second, to understand the depression treatment cascade at the clinic population level, we
categorized the first 24 months of each individual’s person-time in CNICS HIV care by its
depressive severity (not depressed, mild depressive symptoms, depressed) and antidepressant
status (on or not on antidepressants) and stratified by gender and race/ethnicity. Antidepres-
sant status was determined using patient medication records for each person-month under
observation. PHQ-9 measurements were considered valid (i.e. carried forward) for up to 6
months. Person-time was excluded if it had been more than 6 months since the most recent
PHQ-9 measure.
Finally, we used multivariable Cox proportional hazards models to estimate associations
between gender, race/ethnicity, and the following depression treatment cascade outcomes over
24 months: first indication for antidepressant treatment, first receipt of antidepressant medica-
tion, and first receipt of evidence-based antidepressant treatment. The origin was considered
entry into care at the CNICS site for all multivariable analyses and all models included site and
calendar time, modeled using restricted cubic splines. Additional covariates, such as CD4, viral
load, substance use and other mental health disorders, were not included because they likely
represent mediators, rather than confounders, of the relationship between race/ethnicity, gen-
der and depression outcomes. We developed inverse probability of censoring weights to
account for differential LTFU by baseline demographic (age) and clinical factors (depression,
anxiety and viral load suppression) that were associated with LTFU.[47] The likelihood of
receiving active evidence-based depression treatment and achieving depression remission were
not evaluated in multivariable analyses due to limited sample size. All analyses were conducted
using Stata 13 (StataCorp: College Station, TX).
Results
Overall 1,390 persons met our inclusion criteria of having a PHQ-9 measure within one month
of entering HIV care (Table 2) and contributed a total of 17,138 person-months of follow-up
time. There were 24 deaths (2%) during the follow-up period. The proportion of individuals
who were lost to follow-up ranged from 12% when an outcome of indication for antidepressant
treatment was considered, to 19% when an outcome of evidence-based antidepressant treat-
ment was considered. The majority of participants were from Site B (81%). Participants were
largely male (89%), white non-Hispanic (49%) and MSM (68%). Overall, a larger proportion of
men were white non-Hispanic (51%) compared to women (35%), with the largest proportion
of women being black non-Hispanic (38%). Over half of participants (63%) had an unsup-
pressed viral load at entry into CNICS HIV care, and the median CD4 count was 427 cells/
mm3. Substance abuse was common; 16% of participants reported current drug use, 39% past
drug use and 33% high risk alcohol use. Compared to women, men were more likely to report
past drug use (40% versus 33%) and high risk alcohol use (34% versus 24%).
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Table 2. Sociodemographic, clinical andmental health characteristics at entry into care of 1,390 HIV-
infected adults in CNICS.
N (%) or Median (IQR)
Demographic and clinical characteristics1
Age 41 (32, 49)
Gender
Male 1,234 (88.8)
Female 156 (11.2)
Race/ethnicity
White, non-Hispanic 680 (49.1)
Black, non-Hispanic 290 (20.9)
Hispanic 328 (23.7)
Other 87 (6.3)
Risk group
IDU 146 (10.6)
MSM (no IDU) 942 (68.3)
Heterosexual (no MSM or IDU) 237 (17.2)
Other 55 (4.0)
Site
Site A 270 (19.4)
Site B 1,120 (80.6)
Viral load at enrollment
Undetectable, < 50 copies/mL 497 (36.9)
Detectable,  50 copies/mL 849 (63.1)
CD4 count, cells/mm3 427 (230, 639)
 200 301 (21.9)
201–500 532 (38.7)
>500 543 (39.5)
ART use
Efavirenz containing 176 (12.7)
Non-efavirenz containing 345 (24.8)
Not on ART 869 (62.5)
Panic disorder
No panic 921 (67.1)
Some panic symptoms 246 (17.9)
Panic disorder 205 (14.9)
Drug use (excluding marijuana use)
No use 544 (45.3)
Current use 191 (15.9)
Past use 465 (38.8)
High risk alcohol use
Yes 444 (32.8)
No 910 (67.2)
Mental health characteristics over 24 months of follow-up
PHQ-9 indicating depressive symptoms (10) 543 (39.1)
Indication for antidepressant treatment (A) 659 (47.4)
Of A: Initiated antidepressant treatment (B) 290 (44.0)
Of B: Evidence-based antidepressant treatment (C) 116 (40.0)
Of C: Active evidence-based antidepressant treatment 21 (18.1)
Depression remission (at any time over 24 months) 109 (20.1)
1 Missing data: race/ethnicity 0.5%, risk group 0.7%, viral load 3.2%, CD4 count 1.0%, panic disorder 1.3%,
drug use 13.7%, alcohol use 2.6%.
doi:10.1371/journal.pone.0160738.t002
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The prevalence of mental health issues in our cohort was high. At entry into CNICS care,
one third of participants had some indication of panic disorder (either some panic symptoms
or panic disorder). Panic disorder was more common among women than men (27% versus
14%). Over 24 months of follow-up, nearly 40% of participants ever had a PHQ-9 10 indicat-
ing depressive symptoms and almost half (47%) had either a PHQ-9 indicating depressive
symptoms or were on an antidepressant at some point (Table 2; S1 Table). Women were more
likely than men to have a PHQ-9 indicating probable depression (54% versus 37%).
There was a substantial decline in the proportion of patients who progressed to each subse-
quent category along the depression treatment cascade for all genders and race/ethnicities (Fig
2A). However, important disparities existed. Over 65% of women had an indication for antide-
pressant treatment within 24 months of entering CNICS HIV care, while only 45% of men did.
Women also had a higher cumulative probability of receiving antidepressant treatment within
24 months of entering care (39% versus 19% for men). Overall, 40% of individuals who initi-
ated antidepressant treatment received evidence-based antidepressant treatment (Table 2).
However, the vast majority of evidence-based antidepressant treatment was passive (the patient
had a low PHQ-9 score and therefore no clinician action was indicated); only a small propor-
tion was active evidence-based (dose increase or medication switch following a high PHQ-9).
The cumulative probability of having an indication for antidepressant treatment, receiving
antidepressant treatment and for that treatment to be evidence-based was low for both genders
(15% for women and 8% for men). The cumulative probability of active evidence-based treat-
ment was even lower (5% for women and 1% for men). Among persons who had a PHQ-
9 10 (n = 543), 20% experienced depression remission at some point during follow-up,
regardless of antidepressant treatment.
When the depression treatment cascade was stratified by race/ethnicity, 38–49% of persons
in each group had an indication for antidepressant treatment (Fig 2B). However, the cumula-
tive probability of receiving antidepressant treatment (e.g. the probability of having an indica-
tion for antidepressant treatment and subsequently receiving treatment) was higher among
white non-Hispanics (25%) and black non-Hispanics (23%), compared to Hispanics (14%) and
Fig 2. The cumulative probability of moving through the depression treatment cascade, by (A) gender and (B) race/ethnicity. The cumulative probability of
experiencing each depression-related event is defined as the probability of experiencing an event, multiplied by the probability of experiencing each previous
event on the depression treatment cascade.
doi:10.1371/journal.pone.0160738.g002
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persons of other race/ethnicity (10%). The cumulative probability of evidence-based antide-
pressant treatment was also low across all racial/ethnic groups, but again was higher for white
non-Hispanics (10%) and black non-Hispanics (12%), compared to Hispanics (5%) and per-
sons of other race/ethnicity (1%). The cumulative probability of receiving active evidence-
based antidepressant treatment was very low in all racial/ethnic groups (0–2%).
When person-time was stratified by depressive severity and antidepressant use, women
spent considerably more time with depressive symptoms or on antidepressants than men
(approximately 50% versus 30%; Fig 3). However, women also spent more time in remission
while on antidepressants (approximately 15%), compared to men (approximately 5%). When
the proportion of individuals who experienced depression remission (on antidepressant treat-
ment with a PHQ-9 score< 5) was considered, similar results were seen among men (12%)
and women (13%).
When person-time stratified by depressive severity and antidepressant use was considered
by race/ethnicity, the amount of person-time spent on antidepressants was similar between
white non-Hispanics and black non-Hispanics (approximately 15% of person-time for both
groups; Fig 3). Hispanics and those of other race/ethnicity experienced slightly lower propor-
tions of person-time on antidepressants (approximately 10% and 7%, respectively). Across gen-
der and racial/ethnic groups, a sizeable proportion of person-time (approximately 20%) was
spent with depressive symptoms but not on antidepressant treatment.
In multivariable analyses accounting for both gender and race/ethnicity, the largest dispari-
ties in having an indication for antidepressant treatment and receiving treatment persisted by
gender. Compared to men, women were more likely to have an indication for depression treat-
ment (HR 1.54, 95% CI 1.34, 1.78); Table 3). Black non-Hispanics (HR 0.47, 95% CI 0.35,
0.65), Hispanics (HR 0.63, 95% CI 0.44, 0.89) and persons of other race/ethnicity (HR 0.35,
95% CI 0.17, 0.73) were less likely to initiate antidepressant treatment, compared to white non-
Hispanics. Women were also more likely to initiate antidepressant treatment (HR 2.03, 95% CI
1.53, 2.69), and to receive evidence-based depression treatment (HR 1.67, 95% CI 1.03, 2.74).
Compared to white non-Hispanics, all other racial/ethnic groups were also less likely to receive
evidence-based depression treatment, however estimates were imprecise due to limited sample
size. Associations between gender and race/ethnicity with active evidence-based antidepressant
treatment were not evaluated due to small sample size.
Discussion
In our cohort of HIV-infected adults in routine care, almost half of the population had an indi-
cation for antidepressant treatment. There was a substantial decline in the proportion of
patients who proceeded to each subsequent category of the depression treatment cascade: from
having an indication for antidepressant treatment, to starting antidepressant treatment, to
receiving evidence-based antidepressant treatment or active evidence-based antidepressant
treatment. Among those with depressive symptoms, the cumulative probability of receiving
evidence-based antidepressant treatment remained 15% regardless of gender or race/
ethnicity.
Our analysis revealed important disparities between men and women along the depression
treatment cascade for HIV-infected adults. Women were more likely to have an indication for
antidepressant treatment, to start antidepressant treatment and to receive evidence-based anti-
depressant treatment compared to men, even after accounting for race/ethnicity. Since only
11% of the study population were women, data were too sparse to examine gender-by-race
interactions. However, similar rates of lifetime depression have been reported among both
white non-Hispanic and black non-Hispanic women elsewhere.[48] Efavirenz, an antiretroviral
Depression Disparities by Gender and Race/Ethnicity among HIV-Infected Adults
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drug with known psychiatric side effects, could account for some of the gender disparity in
HIV-infected populations.[49] However, in our cohort only 13% of participants were on an
efavirenz containing ART regimen at baseline and of those, only 5% were women. A higher
proportion of depression among women has also been reported in the general US population.
Fig 3. Antidepressant (AD) use and depressive severity, stratified by person-time and (A) gender and (B) race/ethnicity.
doi:10.1371/journal.pone.0160738.g003
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[28] The increased likelihood of women receiving any antidepressant treatment or evidence-
based antidepressant treatment may be related to the fact that women are more likely than
men to seek mental health services.[50, 51] Future analyses should explore possible reasons,
such as domestic violence, economic vulnerability or social support, for gender disparities in
depressive symptoms among PLWH.
Several large surveys of adults in the general US population have found a higher prevalence
of depression among white non-Hispanics compared to black non-Hispanics or Hispanics.[18,
20, 52] In unadjusted analyses, the probability of having an indication for antidepressant treat-
ment was similar across all race/ethic groups (ranging from 38%-49%). However, after adjust-
ing for gender in the multivariable analysis, white non-Hispanics were more likely to have an
indication for antidepressant treatment compared to black non-Hispanics and Hispanics,
although confidence intervals included the null value of 1.00. Women in our cohort were more
likely to be black non-Hispanic (38% versus 19% for men) and depressed (65% versus 45% for
men), which may explain why accounting for gender resulted in a higher burden of depression
on white non-Hispanics relative to other racial/ethnic groups.
In addition to having a higher prevalence of depression, white non-Hispanics in the general
population also disproportionately are prescribed antidepressants and receive treatment in
accordance with clinical guidelines.[21, 23, 24, 53–55] Our analysis demonstrated similar
trends in a HIV-infected population, with white non-Hispanics being more likely to initiate
antidepressant treatment and to receive evidence-based antidepressant treatment than all other
race/ethnicities. The disparity in depression treatment for racial and ethnic minorities may be
related to healthcare access and antidepressant prescribing patters of clinicians. Compared to
white non-Hispanics, black non-Hispanics and Hispanics in the general population are more
likely to be uninsured,[19, 24, 56] are less likely to receive an antidepressant prescription from
a provider[55, 57] and are also less likely to fill an antidepressant prescription.[54] Many HIV-
infected adults have access to HIV medical care through federal Ryan White HIV/AIDS pro-
gram, however coverage for mental health services varies widely by state which may contribute
to the disparity in initiating antidepressant treatment.[58] Non-medication-based depression
interventions, such as counseling, have effectively reduced depression for non-white racial
groups.[59–61] However information on counseling and psychotherapy was not available in
our data.
Our analysis included participants from two sites in the southeastern and western United
States. As a result, our study population was largely male, MSM and had a higher proportion of
black non-Hispanics and Hispanics than HIV-infected adults in the US overall.[62] Our study
results, therefore, are generalizable to similar populations of HIV-infected adults, but may be
less generalizable to HIV-infected adults in the US overall. Further, participants in our analysis
Table 3. Multivariable results for the associations between gender and race/ethnicity with depression-related events.1
Characteristic Indication for Antidepressant Treatment Initiate Antidepressant Treatment Evidence-based Antidepressant Treatment
HR (95% CI) HR (95% CI) HR (95% CI)
Male 1.00 1.00 1.00
Female 1.54 (1.34, 1.78) 2.03 (1.53, 2.69) 1.67 (1.03, 2.74)
White, non-Hispanic 1.00 1.00 1.00
Black, non-Hispanic 0.86 (0.72, 1.03) 0.47 (0.35, 0.65) 0.48 (0.30, 0.79)
Hispanic 0.84 (0.70, 0.99) 0.63 (0.44, 0.89) 0.67 (0.37, 1.19)
Other 0.77 (0.56, 1.04) 0.35 (0.17, 0.73) 0.15 (0.02, 1.09)
1 All models adjusted for variables in the table, site, calendar time and inverse probability of censoring weights for LTFU.
doi:10.1371/journal.pone.0160738.t003
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were receiving HIV care at large academic medical centers, which may have more resources to
screen for and treat depression in HIV-infected populations. Additional work is needed to
characterize the prevalence of depressive symptoms and disparities in depression treatment,
with both antidepressant and counseling-based approaches, for HIV-infected adults receiving
care at smaller, community-based clinics.
Our study has several important limitations. Depressive symptoms were defined in our
cohort as a PHQ-9 score10, which is a validated threshold for identifying probable depres-
sion but is not diagnostic. Further, some antidepressants have secondary indications, such as
bupropion for smoking cessation or duloxetine for pain management and more severe mental
illnesses, such as bipolar disorder, are sometimes misclassified as depressive symptoms. Thus
there may be some measurement error in our estimate of the proportion of the study popula-
tion having an indication for antidepressant treatment. Second, although the CNICS dataset
contains a unique combination of repeated PHQ-9 measures and antidepressant medication
changes, we did not have data on referral to counseling or to additional aspects of the clinical
presentation that might legitimately prompt a clinician not to adjust antidepressant treatment
even in the face of persistent depressive symptoms (for example, concern about side effects at a
higher dose or evidence of patient non-adherence to the prescribed antidepressant dose).
Therefore some of the clinical care classified as “not evidence-based”may have been clinically
appropriate. Finally, our study draws on a large, geographically and racially diverse populations
of HIV-infected adults. However, our analysis was limited to participants at sites where the
PHQ-9 is routinely administered upon entry into CNICS care to ensure a valid measure of
depressive symptoms. Information on whether patients entering CNICS care have a new HIV
diagnosis or have been in care previously is not available in CNICS. Consequently, the high
prevalence of depressive symptoms reported in our study may in part reflect participants deal-
ing with a new diagnosis of HIV.
Conclusions
Our analysis is among the first to characterize disparities in indication, receipt and quality of
antidepressant treatment among HIV-infected adults in routine care. The precipitous drop-
offs we observed along the depression treatment cascade highlight the need to improve access
to high-quality depression care for all HIV-infected adults. Our results also confirm that many
of the disparities in receiving high-quality depression care that exist by gender and race/ethnic-
ity in the general population, persist among HIV-infected adults. In particular, HIV-infected
women appear to be experiencing more depressive symptoms compared to men, and racial/
ethnic minorities are less likely to initiate antidepressants and receive evidence-based treatment
than white non-Hispanics. Given the high burden of depression among HIV-infected adults,
these disparities are particularly concerning. Increasing awareness among mental health and
HIV providers about disparities in depression treatment for HIV-infected adults may help to
close the treatment gap. However, future research should also explore whether different types
of depression treatment interventions (such as antidepressant treatment only or antidepressant
treatment with counseling) are more efficacious for women or racial/ethnic minorities in order
to reduce disparities along the depression treatment cascade.
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